(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) rose by a staggering 33.93% in 21 sessions from €0.11 to €0.15 at 10:13 EST on Monday, after three successive sessions in a row of losses. BEL 20 is sliding 1.3% to €3,697.93, after five consecutive sessions in a row of losses.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Volatility
BIOSENIC’s last week, last month’s, and last quarter’s current intraday variation average was 0.02%, 1.95%, and 6.03%.
BIOSENIC’s highest amplitude of average volatility was 3.55% (last week), 10.08% (last month), and 6.03% (last quarter).
Volume
Today’s last reported volume for BIOSENIC is 8876 which is 88.51% below its average volume of 298733.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC’s stock is considered to be overbought (>=80).
More news about BIOSENIC (BIOS.BR).
